Trials / Recruiting
RecruitingNCT06554197
Evaluation of CMV/EBV-CMI in Haploid HSCT
Evaluation of Cytomegalovirus and Epstein-Barr Virus Specific Immune Reformulation in Prophylaxis for Cytomegalovirus in Haploid Hematopoietic Stem Cell Transplantation
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- The First Affiliated Hospital of Soochow University · Academic / Other
- Sex
- All
- Age
- 16 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this prospective, open-label, Single Arm, single-center study is to evaluate the cytomegalovirus and Epstein-Barr virus specific immune reestablishment for patients with hemopathy undergoingin prophylaxis for cytomegalovirus in haploid hematopoietic stem cell transplantation(haplo-HSCT) .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | CMV/EBV-CMI | The CMV/EBV-CMI is tested before conditioning regimen and 30 days, 45 days, 60 days, 90 days, 120 days, 180 days after transplantation. |
Timeline
- Start date
- 2024-08-13
- Primary completion
- 2025-07-31
- Completion
- 2026-07-31
- First posted
- 2024-08-15
- Last updated
- 2024-08-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06554197. Inclusion in this directory is not an endorsement.